Disease Activity in Psoriasis Affects Specific Sleep Domains but Not Overall Sleep Quality
Lead
Psoriasis is widely recognized for its inflammatory skin manifestations, but its impact on sleep has received far less attention. A new cross-sectional study from two Italian university hospitals suggests that the relationship between psoriasis and sleep is more nuanced than previously thought. While overall sleep quality may not differ dramatically between patients with mild and more severe disease, specific domains of sleep disruption including how long it takes to fall asleep and how well patients function during the day are significantly affected by disease activity. The findings, published in the Journal of Clinical Medicine, point to the need for targeted sleep assessments in psoriasis patients whose skin symptoms are more pronounced.
What They Found
Researchers led by Damiano Currado at the University of Rome Campus Biomedico and Link University of Rome enrolled 136 consecutive psoriasis patients from two dermatology centers in Italy. Disease severity was measured using the Psoriasis Area and Severity Index (PASI), while sleep quality was evaluated with the Pittsburgh Sleep Quality Index (PSQI), a widely used and validated self-report questionnaire that assesses sleep over the previous month.
The study population had relatively mild disease overall, with a median PASI score of 2. On the PSQI, the median score was 5, placing the group at the threshold of clinically meaningful sleep impairment. A global PSQI score above 5 is generally considered indicative of poor sleep quality.
When the researchers split patients into those with PASI scores below 10 and those with scores of 10 or higher, a pattern emerged. Patients with more active disease did not show a statistically significant difference in their global PSQI scores compared to those with milder disease. However, two specific components of the PSQI told a different story.
Patients with PASI scores of 10 or higher had significantly worse sleep latency, meaning they took longer to fall asleep after going to bed (p = 0.01). They also reported significantly greater daytime dysfunction (p = 0.02), including trouble staying awake during daily activities and reduced enthusiasm for getting things done.
The association held up even after the researchers adjusted for potential confounding factors including age, sex, body mass index, and the presence of psoriatic arthritis. In the fully adjusted regression models, a PASI score of 10 or higher independently predicted worse sleep latency (beta = 0.95, 95 percent CI 0.08 to 1.82, p = 0.032) and greater daytime dysfunction (beta = 2.52, 95 percent CI 1.31 to 3.73, p < 0.001).
The authors concluded that psoriasis disease activity affects specific sleep domains rather than global sleep quality. The dissociation between preserved global scores and impaired subdomains suggests that standard overall sleep questionnaires may miss key aspects of sleep disruption in this population.
Why It Matters
This study addresses an underrecognized dimension of the psoriasis burden. Itch, pain, and discomfort from psoriatic lesions are well known to interfere with sleep, but the evidence base linking objective disease severity to measurable sleep outcomes has been inconsistent. By showing that disease activity specifically impairs sleep initiation and daytime functioning rather than global sleep quality, the findings carry several implications.
First, they suggest that clinicians should not rely solely on global sleep questionnaires when assessing psoriasis patients. A patient may have a normal total PSQI score while still struggling significantly with falling asleep or staying alert during the day. These domain-specific deficits can meaningfully affect quality of life and may require separate clinical attention.
Second, the link between disease activity and daytime dysfunction raises the possibility of downstream effects on work performance, mood, and social functioning. Daytime sleepiness in psoriasis patients may be misattributed to depression, medication side effects, or lifestyle factors when the primary driver may actually be disease activity itself.
Third, the findings reinforce the importance of achieving adequate skin clearance as a therapeutic goal. If more severe psoriasis directly impairs sleep latency and daytime function, then effective treatment that lowers PASI scores may have benefits that extend beyond the skin to include sleep and daily functioning. Biologic therapies and other advanced treatments that produce clear or almost clear skin could plausibly improve these sleep domains, though the study did not test this directly.
The study is also notable for what it did not find. The lack of a significant difference in global PSQI scores between groups may reflect the relatively mild disease in the sample, but it may also indicate that the PSQI global score is not sensitive enough to capture the sleep effects of psoriasis. If confirmed, this could prompt a reevaluation of how sleep outcomes are measured in dermatology research.
Limits
The study has important limitations. As a cross-sectional design, it cannot establish causality. It is possible that preexisting sleep problems aggravate psoriasis through neuroimmune mechanisms, or that a third factor such as stress, obesity, or depression independently drives both skin and sleep symptoms. Longitudinal studies would be needed to clarify directionality.
The sample was relatively small at 136 patients and drawn from two specialized centers in Italy, which may limit generalizability. The median PASI of 2 indicates that the cohort was skewed toward mild disease. Only a small number of patients had PASI scores of 10 or higher, and the study did not report exactly how many fell into this category. This limited subgroup may reduce the precision of the estimates.
The PSQI is a subjective, self-reported measure of sleep and does not capture objective sleep parameters such as total sleep time, sleep efficiency, or nocturnal awakenings as measured by actigraphy or polysomnography. Patients with psoriasis may overreport or underreport sleep difficulties depending on their mood, itch perception, or other factors.
Additionally, the study did not assess itch severity directly, which is a major confound in the psoriasis-sleep relationship. Itch is one of the most common symptoms driving sleep disruption in psoriasis, and without measuring it, separating the effects of disease activity on sleep from the effects of itch is difficult.
Bottom Line
Psoriasis disease activity does not necessarily impair overall sleep quality as measured by global scores, but it does affect specific and clinically meaningful sleep domains. Patients with more severe skin disease take longer to fall asleep and experience more daytime dysfunction. Clinicians should consider domain-specific sleep assessments rather than relying only on global sleep indices, and achieving better skin control may help improve these particular aspects of sleep health. Further research with objective sleep measures and itch assessment in more diverse populations is needed.
Source
Currado D, Conforti C, Trunfio F, et al. Disease Activity-Related Sleep Dysfunction in Psoriasis: Insights from a Cross-Sectional Study. Journal of Clinical Medicine. 2026;15(11):4198. doi:10.3390/jcm15114198. PMID: 42279059.